Burger Recall Update as FDA Sets Highest Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A recall of seafood burgers has been issued a Class I risk classification by the U.S. Food and Drug Administration (FDA).
The recall was initiated earlier this month by the Connecticut based company Caraluzzi's Markets due to the undeclared presence of egg, a major food allergen.
Newsweek has contacted Caraluzzi's Markets for comment outside of regular working hours.
Caraluzzi's Markets initiated a voluntary recall of its Italian-style seafood burgers earlier this month due to the undeclared presence of egg.
Caraluzzi's Markets initiated a voluntary recall of its Italian-style seafood burgers earlier this month due to the undeclared presence of egg.
Caraluzzi's Markets
Why It Matters
Eggs are one of the nine major food allergens, as defined in law. The others include milk, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.
Egg allergies are common and in rare cases can lead to anaphylaxis — a severe and potentially fatal reaction. When an allergen is not properly listed on food packaging, it puts unsuspecting consumers at risk.
For those who are sensitive to any of these foods, they can have a reaction within minutes or hours, and symptoms can range from mild to life-threatening.
What To Know
Caraluzzi's Markets initiated a recall on April 8 for its eight-ounce Italian Style Seafood Burgers because the packaging did not reveal the presence of egg.
The affected product was distributed and sold between February 18 and April 2, 2025, at Caraluzzi's Markets locations in Bethel, Wilton, Newtown, and Danbury. Connecticut is the only state affected by the recall, according to the FDA report.
The burgers that were part of the recall had an expiration date of January 16, 2026, with the UPC code 0-95864-80008-8.
The FDA issued its Class I classification on April 30, meaning it is a "situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
The labeling error came to light following a consumer complaint that prompted an internal investigation by Caraluzzi's Markets.
As of April 8, one allergic reaction had been reported. It is not clear if any other allergic reactions have occurred.
The mislabeled burgers have been removed from store shelves, but the recall is ongoing, according to the FDA.
What People Are Saying
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, told Newsweek previously: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last 5, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
Customers who purchased the product are urged not to eat it and to return it to the place of purchase for a full refund.
Consumers with questions about the recall are encouraged to contact Caraluzzi's Markets at 203-748-3547, via email at customerservice@caraluzzis.com, or in person at any store customer service desk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
WebMD
2 hours ago
- WebMD
FDA Approves New 3-in-1 Combo Pill for High Blood Pressure
June 11, 2025 – The FDA has approved a new pill for adults with high blood pressure (hypertension) that combines three medicines in one. Available in one regular and two lower doses, it offers a convenient option for treating hypertension, which affects nearly half of the adults in the U.S. and raises their risk of stroke and heart failure. Sold as Widaplik, it is the first and only single pill to combine three previously FDA-approved drugs – telmisartan, amlodipine, and indapamide – offering a triple-action approach for people who would otherwise need multiple pills to manage their blood pressure. It works in three ways and is a safe, well-tolerated early treatment option. Hypertension happens when your blood pushes too hard against your blood vessels, making the heart work harder and increasing the risk of heart problems, strokes, and other complications. It contributes to about 460,000 deaths annually in the U.S. and often goes undetected due to a lack of symptoms. With 1 in 3 Americans unaware they have it and only 1 in 4 managing it well, there's an urgent need for simpler, more effective treatments. The approval was based on two large studies that showed using Widaplik helped lower blood pressure more than using just two medicines or a placebo, according to a news release from the company that makes it, George Medicines. People who took Widaplik didn't stop taking it more often because of side effects, which means it was generally easy for them to take. Another trial showed that Widaplik was better at reducing blood pressure compared to standard care, while remaining well-tolerated. George Medicines stated that a global trial is underway to find out if the combo treatment can help prevent strokes in people who have previously had an intracerebral hemorrhage (sudden bleeding in the brain), the most serious type of stroke. "Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide. Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment," Paul Whelton, MD, Show Chwan chair of global public health at Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. Widaplik is a medicine made of three drugs that work together to help lower blood pressure. Two of them, telmisartan and amlodipine, relax blood vessels so blood can flow more easily. The third, indapamide, helps your body get rid of extra water by making you pee more. Widaplik comes in three strengths: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Low blood pressure – which can make you feel faint or dizzy – was the most common side effect, the company said. Patients who pass out should stop taking the medication and consult their doctor.
Yahoo
2 hours ago
- Yahoo
Urgent fish recall issued over botulism concerns
Fish sold in multiple U.S. states have been urgently recalled because they may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death. P. East Trading Corp. is recalling its Salted Smoked Split Herring, according to a press release shared by the U.S. Food and Drug Administration (FDA) on Tuesday. The product is five inches in length and uneviscerated, meaning they had not had its internal organs removed. According to the FDA, the recalled fish may contain Clostridium botulinum spores that cause botulism, 'as they are more likely to be concentrated in the viscera than any other portion of the fish.' Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation. The recall came after the Salted Smoked Split Herring was sampled by a New York State Department of Agriculture and Markets Food Inspector. A subsequent analysis of the product confirmed that the 'herring was not properly eviscerated prior to processing.' There have been no reported illnesses so far. The recalled fish was sold at retail locations in Connecticut, New Jersey, and New York. It was sold in 18-pound wooden boxes with the container code Lot 1 PRC5073. However, the FDA noted that the product could have been repacked by retail store workers in 'deli-style or other retail packaging.' A specific list of the stores that received and potentially sold the herring can be found here. Consumers are urged not to eat the recalled herring. Instead, they should return the product to the place of purchase for a full refund. This isn't the only product that's been recalled due to a risk of botulinum. In April, Walker's Wine Juice recalled its pumpkin juice, sold in 12 states, because it may have contained the potentially fatal form of food poisoning. The recall was issued after the New York State Department of Agriculture and Markets Food Inspectors discovered the juice's pH was 'too high to be processed per Walker's 'hot fill' schedule process.' The recall applied to all lots of Walker's Wine Juice's 2.5-gallon bag in a box and 5-gallon hot pack labeled 'pumpkin' in addition to their 30-, 60-, and 275-gallon bulk containers also labeled 'pumpkin.' The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023. In May, cucumbers sold across the country were recalled after people in 15 states reported getting ill from salmonella. Florida-based Bedner Growers, Inc. recalled the vegetables distributed by Fresh Start Produce Sales, Inc. from April 29 to May 19.
